Abstract: An active energy ray liquid composition is provided. A cured product of the active energy ray curable liquid composition is a solid at 25° C. and a liquid at 60° C., and the solid exhibits a compression stress of 2.0 kPa or more when compressed 1%.

Abstract: A solid freeform fabrication material set includes a first solid freeform fabrication liquid material including a solvent, a resin A soluble in the solvent, and an inorganic particle; and a second solid freeform fabrication liquid material including a resin B soluble in water and a second colorant.

Abstract: A solid freeform fabrication object includes a hydrogel including a polymer, water, and a coloring material inclusion substance.

Abstract: Provided is a medical device including a porous portion and a dense portion, wherein an arithmetic average roughness of a surface of the porous portion is 2.0 ?m or greater but 20 ?m or less, and wherein an arithmetic average roughness of a surface of the dense portion is less than 2.0 ?m.

Abstract: A solid freeform fabrication material set includes a material A for solid freeform fabrication and a material B for solid freedom fabrication. The material A includes a polymerization initiator A and at least one of an organic particle and an inorganic particle. The material B includes a polymerizable compound B.

Abstract: Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as, for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action, and completed the present invention. That is, the dihydroxy aromatic heterocyclic compound of the present invention has a good DAAO inhibitory action, and can be used as a prophylaxis and/or therapeutic agent for, for example, schizophrenia or neuropathic pain.

Abstract: Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action, and completed the present invention. That is, the dihydroxy aromatic heterocyclic compound of the present invention has a good DAAO inhibitory action, and can be used as a prophylaxis and/or therapeutic agent for, for example, schizophrenia or neuropathic pain.

Abstract: A hydrogel object includes a polymer and water, wherein the rate of mass loss is not greater than 20 percent by mass when the hydrogel object is left undone for one week at 25 degrees C. and relative humidity of 50 percent.

Abstract: A method of manufacturing a three-dimensional object includes imparting a first liquid having a first composition including a solvent and a curable material and a second liquid having a second composition to form a liquid film, curing the liquid film, and repeating the imparting and the curing to obtain the three-dimensional object, wherein the imparting position and the imparting amount of each of the first liquid and the second liquid are controlled in such a manner that the liquid film includes multiple areas where at least one of post-curing compression stress and post-curing modulus of elasticity is different.

Abstract: Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action, and completed the present invention. That is, the dihydroxy aromatic heterocyclic compound of the present invention has a good DAAO inhibitory action, and can be used as a prophylaxis and/or therapeutic agent for, for example, schizophrenia or neuropathic pain.

Abstract: Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action, and completed the present invention. That is, the dihydroxy aromatic heterocyclic compound of the present invention has a good DAAO inhibitory action, and can be used as a prophylaxis and/or therapeutic agent for, for example, schizophrenia or neuropathic pain.

Abstract: Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as, for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action, and completed the present invention. That is, the dihydroxy aromatic heterocyclic compound of the present invention has a good DAAO inhibitory action, and can be used as a prophylaxis and/or therapeutic agent for, for example, schizophrenia or neuropathic pain.

Abstract: To provide an electrophotographic photoconductor that has a layer containing a compound represented by the following general formula (1), and an image forming apparatus using the electrophotographic photoconductor. where R1 and R2 independently represent any one of a hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group and substituted or unsubstituted aralkyl group, and R3, R4, R5, R6, R7, R8, R9 and R10 independently represent any one of a hydrogen atom, halogen atom, cyano group, nitro group, amino group, hydroxyl group, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group and substituted or unsubstituted aralkyl group.

Abstract: An electrophotographic photoreceptor, including an electroconductive substrate; and a photosensitive layer overlying the substrate, wherein the photosensitive layer comprises a complex azo pigment comprising an azo compound having the following formula (a): A(H)n??(a) wherein A represents a residue of an azo compound, bonded with n pieces of hydrogen atom through one or more heteroatom being N or O and forming a part of the residue A; H represents a hydrogen atom; and n represents an integer of from 1 to 9, and a pigment.

Abstract: An image bearing member having a substrate and a layer provided overlying the substrate, which has a cured material in which a compound comprising three or more methylol groups and a charge transport group is cross-linked.

Abstract: To provide an electrophotographic photoconductor that has a layer containing a compound represented by the following general formula (1), and an image forming apparatus using the electrophotographic photoconductor.

Abstract: To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17?HSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17?HSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

Abstract: An image forming apparatus is provided, including an electrostatic latent image bearer; a charger charging the electrostatic latent image bearer; an irradiator irradiating the electrostatic latent image bearer with imagewise light having an image resolution not less than 1,200 dpi to form an electrostatic latent image thereon; an image developer developing the electrostatic latent image with a toner to form a toner image on the electrostatic latent image bearer; a transferer transferring the toner image onto a recording medium; and a fixer fixing the toner image on the recording medium, wherein a time for a given point on the electrostatic latent image bearer to travel from a position right in front of the irradiator to a position right in front of the image developer is shorter than 50 msec and longer than a transit time of the electrostatic latent image bearer, and an image forming method using the image forming apparatus.

Abstract: To provide an electrophotographic photoconductor that has a layer containing a compound represented by the following general formula (1), and an image forming apparatus using the electrophotographic photoconductor. where R1 and R2 independently represent any one of a hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group and substituted or unsubstituted aralkyl group, and R3, R4, R5, R6, R7, R8, R9 and R10 independently represent any one of a hydrogen atom, halogen atom, cyano group, nitro group, amino group, hydroxyl group, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group and substituted or unsubstituted aralkyl group.

Abstract: To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17?HSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17?HSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.